Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Biodesix, Inc. before investing.

In this article, we go over a few key elements for understanding Biodesix, Inc.’s stock price such as:

• Biodesix, Inc.’s current stock price and volume
• Why Biodesix, Inc.’s stock price changed recently
• Upgrades and downgrades for BDSX from analysts
• BDSX’s stock price momentum as measured by its relative strength

About Biodesix, Inc. (BDSX)

Before we jump into Biodesix, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Want to learn more about Biodesix, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Biodesix, Inc..

Biodesix, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Biodesix, Inc.’s stock price was $21.200.

Biodesix, Inc. is down 0.63% from its previous closing price of $21.335.

During the last market session, Biodesix, Inc.’s stock traded between $21.000 and $21.890. Currently, there are approximately 9.66 million shares outstanding for Biodesix, Inc..

Biodesix, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Biodesix, Inc. Stock Price History

Biodesix, Inc.’s (BDSX) price is currently down 5.99% so far this month.

During the month of July, Biodesix, Inc.’s stock price has reached a high of $24.920 and a low of $18.910.

Over the last year, Biodesix, Inc. has hit prices as high as $24.915 and as low as $5.260. Year to date, Biodesix, Inc.’s stock is up 211.76%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Biodesix, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Biodesix, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Biodesix, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Biodesix, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Biodesix, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Biodesix, Inc. (BDSX) by visiting AAII Stock Evaluator.

Relative Price Strength of Biodesix, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Biodesix, Inc. has a weighted four-quarter relative price strength of 42.77%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Biodesix, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Biodesix, Inc. Stock Price: Bottom Line

As of July 31, 2026, Biodesix, Inc.’s stock price is $21.200, which is down 0.63% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Biodesix, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.